Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) ended Friday session in red amid volatile trading. The shares closed down -0.01 points or -0.30% at $3.35 with 1.21 million shares getting traded. Post opening the session at $3.35, the shares hit an intraday low of $3.23 and an intraday high of $3.38 and the price vacillated in this range throughout the day. The company has a market cap of $340.89 million and the numbers of outstanding shares have been calculated to be 100.55 million shares.
Celldex Therapeutics, Inc. (CLDX) on Aug. 11, 2016 announced that the Company has promoted Elizabeth Crowley to the newly created position of Senior Vice President, Chief Product Development Officer. Ms. Crowley was previously Senior Vice President of Product Development of Celldex and brings almost 25 years of industry experience where she was responsible for leading the execution of multiple successful drug development programs.
“Celldex was founded on the belief that combination regimens designed to unlock the power of the immune system would deliver the greatest benefit to the largest population of patients,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. “This newly created position is a direct response to the future of portfolio planning and drug development in the immuno-oncology field where we believe multi-drug combination regimens will become the norm and the development programs to explore these opportunities will become increasingly complex. Beth’s deep, oncology-focused experience in strategic planning, portfolio management and implementation have played a critical role in building the depth and breadth of our pipeline to date and an exceptional development operations team here at Celldex. We look forward to her continued expertise in this expanded leadership role.”
“Celldex has thoughtfully seeded a pipeline with individual product candidates that uniquely manipulate the immune system at key points,” said Ms. Crowley. “With successful proof of concept work achieved, we have now entered the next phase of development and are extensively exploring multi-drug combination regimens. I look forward to working closely with my Celldex colleagues across the organization as we expand this approach in our ongoing efforts to improve outcomes for patients and their families.”
Shares of HCA Holdings Inc (NYSE:HCA) ended Friday session in green amid volatile trading. The shares closed up +1.35 points or 1.80% at $76.51 with 2.11 million shares getting traded. Post opening the session at $75.56, the shares hit an intraday low of $75.35 and an intraday high of $76.68 and the price vacillated in this range throughout the day. The company has a market cap of $28.82 billion and the numbers of outstanding shares have been calculated to be 378.65 million shares.
HCA Holdings Inc (HCA) is scheduled to present at the following healthcare conferences in September 2016.
September 8, 2016 at 10:15 a.m. (EDT) at the Baird 2016 Global Healthcare Conference held at The New York Palace, New York, NY.
September 14, 2016 at 10:30 a.m. (EDT) at the Morgan Stanley Global Healthcare Conference held at the Grand Hyatt New York, New York, NY.
A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.
Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company’s website for the latest information.